• 1
    Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 13953.
  • 2
    Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40: 7883.
  • 3
    Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North Am 1990; 16: 7591.
  • 4
    Herrick A, Diagnosis and management of scleroderma peripheral vascular disease. Rheum Dis Clin North Am 2008; 34: 89114.
  • 5
    Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl: iii1924.
  • 6
    Zelenietz C, Pope J. Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan [letter]. Ann Rheum Dis 2010; 69: 20556.
  • 7
    Grey JE, Enoch S, Harding KG. Wound assessment. Br Med J 2006; 332: 2858.
  • 8
    Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D. Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manage 2003; 49: 2451.
  • 9
    Gastmeier P, Stamm-Balderjahn, Hansen S, Nitzschke-Tiemann F, Zuschneid I, Groneberg K, et al. How outbreaks can contribute to prevention of nosocomial infection: analysis of 1,022 outbreaks. Infect Control Hosp Epidemiol 2005; 26: 35761.
  • 10
    Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011; 70: 328.
  • 11
    Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum 2007; 56: 198593.
  • 12
    Opitz C, Klein-Weigel PF, Riemekasten G. Systemic sclerosis: a systematic overview. Part 2: immunosuppression, treatment of SSc-associated vasculopathy, and treatment of pulmonary arterial hypertension. Vasa 2011; 40: 2030.
  • 13
    Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010; 69: 14758.
  • 14
    Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Misra R, et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010; 49: 24208.
  • 15
    Ambach A, Seo W, Bonnekoh B, Gollnick H. Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil. J Dtsch Dermatol Ges 2009; 7: 88891.
  • 16
    Schultz G, Mozingo D, Romanelli M, Claxton K. Wound healing and TIME: new concepts and scientific applications. Wound Repair Regen 2005; 13: S111.
  • 17
    Longtin Y, Sax H, Allegranzi B, Schneider F, Pittet D. Hand hygiene. N Engl J Med 2011; 364: e24.
  • 18
    Larson E. A casual link between handwashing and risk infection? Examination of the evidence. Infect Control 1988; 9: 2836.